NovaBridge (NBP) CEO awarded 3M options vesting over four years

Rhea-AI Filing Summary

NovaBridge Biosciences reported that Chief Executive Officer Srishti Gupta received a grant of 3,000,000 employee share options. These options give the right to buy Ordinary Shares at an exercise price of $2.01 per ADS-equivalent and expire on July 6, 2036. The award vests in four equal annual installments beginning on the first anniversary of July 1, 2026, and Gupta now holds 3,000,000 such options directly.

Insights

Equity compensation analyst

CEO receives a large, multi-year option grant as standard equity compensation.

The CEO of NovaBridge Biosciences, Srishti Gupta, received 3,000,000 employee share options with an exercise price of $2.01 per ADS-equivalent. These options are derivative securities that allow future purchase of Ordinary Shares if conditions are met.

The options vest in four equal annual installments starting on the first anniversary of July 1, 2026, and expire on July 6, 2036. This structure ties compensation to long-term share performance and service, while not reflecting any open-market buying or selling activity in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gupta Srishti

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	2025 Employee Share Option (right to buy)	3,000,000	$0.00	--

Holdings After Transaction: 2025 Employee Share Option (right to buy) — 3,000,000 shares (Direct, null)

Footnotes (1)

1. Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS"). The option vests and becomes exercisable in four equal annual installments beginning on the first anniversary of July 1, 2026. The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

Key Figures

Option grant size: 3,000,000 options Exercise price: $2.01 per ADS-equivalent Expiration date: July 6, 2036 +4 more

7 metrics

Option grant size 3,000,000 options 2025 Employee Share Option grant to CEO

Exercise price $2.01 per ADS-equivalent Exercise price for granted options

Expiration date July 6, 2036 Option term end date

Underlying securities 3,000,000 Ordinary Shares Underlying security for options

ADS to Ordinary ratio 10 ADSs = 23 Ordinary Shares Representation of Ordinary Shares by ADSs

Post-grant option holdings 3,000,000 options Total derivative securities held after transaction

Vesting schedule 4 equal annual installments Beginning on first anniversary of July 1, 2026

Key Terms

Employee Share Option, American Depositary Shares, exercise price, vests and becomes exercisable, +1 more

5 terms

Employee Share Option financial

"2025 Employee Share Option (right to buy)"

American Depositary Shares financial

"Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS")."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

exercise price financial

"Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS")."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests and becomes exercisable financial

"The option vests and becomes exercisable in four equal annual installments"

Ordinary Shares financial

"The Ordinary Shares may be represented by ADSs."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/08/2026 - 04:26 PM Accepted by SEC EDGAR 07/08/2026 - 04:26 PM Learn about SEC filing dates

FAQ

What did NovaBridge Biosciences (NBP) CEO receive in this Form 4 filing?

NovaBridge Biosciences CEO Srishti Gupta received 3,000,000 employee share options. These options allow future purchases of Ordinary Shares at a fixed exercise price, functioning as equity-based compensation rather than an open-market stock purchase or sale.

What is the exercise price of the options granted to NovaBridge (NBP) CEO?

The granted options have an exercise price of $2.01 per ADS-equivalent. This means Gupta can buy the underlying Ordinary Shares at that price once the options vest and are exercised, assuming she chooses to do so within the option term.

When do the NovaBridge (NBP) CEO stock options vest and become exercisable?

The options vest in four equal annual installments beginning on the first anniversary of July 1, 2026. Each year, one quarter of the 3,000,000 options becomes exercisable, linking potential value to Gupta’s continued service over several years.

What is the expiration date of the options granted to NovaBridge (NBP) CEO?

The options granted to the NovaBridge CEO expire on July 6, 2036. After this date, any unexercised options become worthless, which encourages exercise only if the share price exceeds the $2.01 exercise price before expiration.

How many NovaBridge (NBP) options does the CEO hold after this transaction?

Following this grant, Srishti Gupta holds 3,000,000 employee share options directly. This figure reflects the total derivative position reported in the filing and represents a significant equity-linked component of her compensation package.

How do NovaBridge (NBP) ADSs relate to Ordinary Shares in this filing?

The filing notes that Ordinary Shares may be represented by ADSs, where each 10 ADSs represent 23 Ordinary Shares. The number of underlying securities and the exercise price are expressed in terms of ADSs for clarity in this equity award.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gupta Srishti

(Last) (First) (Middle)

C/O NOVABRIDGE BIOSCIENCES

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
2025 Employee Share Option (right to buy)	$2.01(1)	07/06/2026		A		3,000,000(1)		(2)	07/06/2036	Ordinary Shares(3)	3,000,000(1)	$0	3,000,000(1)	D

Explanation of Responses:

1. Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS").

2. The option vests and becomes exercisable in four equal annual installments beginning on the first anniversary of July 1, 2026.

3. The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

	/s/ Kyler Lei as attorney-in-fact	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)